Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 8,44 € (+6,03 %). La mediana es de 8,17 € (+2,64 %).
| Comprar |
15 |
| Mantener |
27 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
BetterHelp and Sophia Bush launch The Permission Project to address women's mental health
BetterHelp launched The Permission Project, a therapist-developed initiative partnered with Sophia Bush that provides a Rewrite Guide, 10,000 hours of free therapy and a $100,000 investment in therapists focused on women’s mental health. The program is based on research identifying social tensions—like being ambitious but likeable—that correlate with rising anxiety and depression among women and offers actionable steps to counter them. Bush, who contributed to the project, emphasizes systemic causes of women's unrecognized labor and the need for cultural change alongside individual support. » Más en forbes.com
Teladoc Health appoints Michael Grasher as chief financial officer
Teladoc Health has appointed Michael Grasher as CFO, effective immediately. Grasher has more than 30 years of experience in the insurance and financial services sector, including over 12 years in CFO roles at companies such as IFG Companies, Fortegra and AMERISAFE, and he also spent many years in equity research. » Más en de.investing.com
Teladoc Health appoints Mark V. Anquillare to the board of directors
Teladoc Health has appointed Mark V. Anquillare, former president and COO of Verisk Analytics, to its board of directors. He will serve on the audit and compensation committees and brings more than 30 years of experience in finance and leadership roles, including overseeing Verisk’s 2009 IPO. Anquillare also sits on several other boards; Teladoc Health provides virtual healthcare services through partnerships with insurers, employers and health systems. » Más en de.investing.com
Teladoc reports revenue decline and cuts annual forecast – stock falls sharply
Teladoc reported Q2 revenue of $606.9 million, missing the analyst consensus of about $615 million, while adjusted EPS of -$0.21 beat expectations. Consumer segment BetterHelp shrank 12% to $212.6 million. For Q3 management expects revenue of $569–609 million and lowered the full-year guidance to $2.36–2.45 billion (previously $2.48–2.58 billion), which weighed heavily on the stock in premarket trading. CEO Chuck Divita cited provider capacity constraints as the reason for weaker revenue realization; over the past six months there have been only insider sales. » Más en de.investing.com
Teladoc plunges about 24% after Q2 results and weak outlook
Teladoc reported a Q2 EPS loss of -$0.21 with revenue of $606.9 million, missing consensus. The Q3 outlook of $569–609 million is well below the $629 million consensus, and the full-year loss forecast was lowered to -$1.00 to -$0.75. The combination of a revenue miss, reduced guidance and continued drag from the BetterHelp segment triggered the sharp share decline. Investors are now awaiting management comments on the conference call for signs of a return to revenue growth. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 534,21 M | 0,08 % |
| Beneficio bruto | 366,25 M | 2,15 % |
| Beneficio neto | -23,78 M | 43,63 % |
| EBITDA | 61,03 M | 54,17 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 1458,5 M € |
Número de acciones | 182,29 M |
Máximo/mínimo de 52 semanas | 8,98 € - 3,99 € |
| Dividendos | No |
Beta | 1,97 |
Ratio P/E | -10,25 |
Ratio PEG | -0,25 |
Ratio P/B | 1,24 |
Ratio P/S | 0,65 |
Perfil de la empresa
Teladoc Health, Inc. ofrece servicios de atención médica virtual en Estados Unidos y a nivel internacional. La compañía ofrece una cartera de servicios y soluciones que cubre afecciones médicas no urgentes, episódicas, crónicas y complejas, incluidas la diabetes, la hipertensión, la enfermedad renal crónica, el cáncer, la insuficiencia cardíaca congestiva y las afecciones de salud mental. Ofrece una serie de programas y servicios, entre ellos soluciones de telesalud para atención primaria y especializada, gestión de enfermedades crónicas, servicios médicos especializados, soluciones de salud mental y servicios de plataforma y programas. La compañía atiende a empleadores, planes de salud, hospitales y sistemas de salud, y compañías de seguros y servicios financieros, así como a miembros particulares. Ofrece sus productos y servicios bajo las marcas Teladoc, Livongo y BetterHelp. La compañía era conocida anteriormente como Teladoc, Inc. y cambió su nombre a Teladoc Health, Inc. en agosto de 2018. La compañía se constituyó en 2002 y tiene su sede central en Purchase, Nueva York.
| Nombre | Teladoc Health |
| CEO | Charles Divita |
| Sede | New York,
ny Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Proveedores y servicios sanitarios |
| Salida a bolsa | 30/06/2015 |
| Empleados | 5124 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NYSE | TDOC |
London Stock Exchange | 0LDR.L |
XETRA | 4LL.F |
Frankfurt | 4LL.F |
Düsseldorf | 4LL.DU |
London | 0LDR.L |
SIX | 4LL.SW |
München | 4LL.MU |